SARS-CoV-2 vaccine and increased myocarditis mortality risk: A population based comparative study in Japan
View ORCID ProfileSintaroo Watanabe, View ORCID ProfileRokuro Hama
doi: https://doi.org/10.1101/2022.10.13.22281036
Sintaroo Watanabe
1Japan Marine United Corporation, Kure Shipyard, Kure, Japan
MD, PhDRokuro Hama
2Non-profit Organization “Japan Institute of Pharmacovigilance (Med Check)”, Osaka, Japan
MDArticle usage
Posted October 18, 2022.
SARS-CoV-2 vaccine and increased myocarditis mortality risk: A population based comparative study in Japan
Sintaroo Watanabe, Rokuro Hama
medRxiv 2022.10.13.22281036; doi: https://doi.org/10.1101/2022.10.13.22281036
Subject Area
Subject Areas
- Addiction Medicine (405)
- Allergy and Immunology (715)
- Anesthesia (209)
- Cardiovascular Medicine (2989)
- Dermatology (254)
- Emergency Medicine (447)
- Epidemiology (12872)
- Forensic Medicine (12)
- Gastroenterology (840)
- Genetic and Genomic Medicine (4667)
- Geriatric Medicine (428)
- Health Economics (735)
- Health Informatics (2969)
- Health Policy (1079)
- Hematology (394)
- HIV/AIDS (941)
- Medical Education (433)
- Medical Ethics (116)
- Nephrology (478)
- Neurology (4449)
- Nursing (239)
- Nutrition (654)
- Oncology (2316)
- Ophthalmology (659)
- Orthopedics (261)
- Otolaryngology (329)
- Pain Medicine (287)
- Palliative Medicine (85)
- Pathology (505)
- Pediatrics (1207)
- Primary Care Research (506)
- Public and Global Health (7047)
- Radiology and Imaging (1563)
- Respiratory Medicine (927)
- Rheumatology (447)
- Sports Medicine (389)
- Surgery (495)
- Toxicology (60)
- Transplantation (214)
- Urology (186)